With the aim of further clarifying the clinical significance of MAGOH upregulation in GC tissues, using the Kaplan–Meier plotter database (5 datasets: GSE14210, GSE15459, GSE22377, GSE29272 and GSE51105), we demonstrated that high MAGOH/MAGOHB expression was significantly associated with shorter overall survival (OS) and first progression survival (FPS) in GC patients, as shown in Fig. 2E, F. To further verify this difference in expression, we also used RT‒qPCR to measure the expression of MAGOH in the clinical samples of 60 GC patients. Here, MAGOH is linked to gastric cancer.